Hytera Group Harvests Five Prestigious ICCA Awards for Innovations and Market Excellence
Hytera, a leading global provider of professional communications technologies and solutions, together with its subsidiaries Sepura and Teltronic, won awards in 5 categories at the International Critical Communications Awards (ICCAs) 2022 held in Vienna, Austria. The ICCAs, presented by The Critical Communications Association (TCCA), are the most prestigious awards in critical communications celebrating the very best of the sector across a variety of verticals and recognizing those who have made significant and individual contributions to the critical communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005515/en/
Hytera Group Wins Five ICCA Awards in Critical Communications (Graphic: Business Wire)
Hytera was firstly awarded “Best Use of Critical Communications in Transport” for a Sri Lanka Railway (SLR) Telecommunications Project. This project enabled Hytera’s 3GPP-compliant MCS Solution to interconnect the SLR sites and provide railway personnel with real-time access to critical data. This allowed them to better serve passengers and provide a smooth and safe operation for train drivers by improving punctuality and reducing railway accidents.
Sepura also claimed an ICCA award for “Best Use of Critical Communications in Mining, Oil & Gas” for the AutoMate App SPACE Application and SCG22 Mobile Radio which was part of the National Wireless Mining Solution. The solution contributed to the operational performance and safety of staff by enabling radio automation through geo-fencing and situational triggers in iron ore mines in Australia.
The SCU3, Sepura’s latest broadband vehicle device, won “Best MX-C Device of the Year”. This technology aroused considerable interests amongst professional communication users looking for future-proof, powerful data capability to enhance their communications solutions.
Sepura’s Senior Specialist Diana Ball was recognized for her “Outstanding Contribution to Critical Communications” for the development of TETRA standards that are still trusted by users to ensure interoperability between suppliers.
Teltronic’s EDESUR project was next awarded “Best Use of Critical Communications in Utilities”. The NEBULA TETRA infrastructure allowed a private electricity distribution company in Argentina to realize the real-time monitoring and fault detection of a power distribution network, and further improve company management and operational efficiency thanks to Teltronic’s unique SDM (Synchronous Data Management) technology.
In addition to securing these awards, Hytera Group was also shortlisted for a number of additional categories including:
Best MC-X Device of the Year
Hytera PDM680 Rugged MCS Radio
Teltronic RTP-800, the First MCX Cab Radio for Transport
Best MC-X solutions of the year
Sepura SCU3 Broadband Vehicle Device
Best TETRA Device of the Year
Hytera PTC680 Multi-mode Radio
Sepura SCG22 Mobile TETRA Radio
Best Use of Advanced Technology
Hytera AI-based Noise Cancellation for Two-way Radios
Best Use of Critical Communications in Public Safety
Teltronic: RESCAN, Reliability and Maximum Coordination in the Fight against the Volcano
Best Use of Critical Communications in Transport
Hytera: Kazakhstan Railway Runs Safely and Efficiently with TETRA Communications System
Emerging Technology, Product or Solutions
Hytera PNC560, World’s First 5G MCPTT Device
Recently Hytera has released a number of innovations from its wide range of product lines, including the latest H-Series DMR Radios, Body-worn Cameras, PTToC Radios & MCS Radios, Multi-mode Rugged Radio and 5G Xsecure Rugged Device. Also the newly launched Hytera Convergence-Native Solutions (including HyTalk, HyTalk Pro and HyTalk MC), composed of different modules, integrates existing network infrastructures, unifies the network core and the communication platform, and provides open API for new service deployment.
With cutting-edge critical communication technologies, Hytera will continue to bring value to global customers leveraging its technologies and professionals.
For more information about Hytera at ICCAs 2022, please visit: https://www.hytera.com/en/media-center/event/hytera-group-won-international-critical-communication-awards.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005515/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
